Professor | Wan-Liang Lu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Wan-Liang Lu
Contact Information	luwl@bjmu.edu.cn
Language ability	Chinese, English
Province	Beijing

Upload Avatar (500 x 500)

Name

Wan-Liang Lu

Contact Information

luwl@bjmu.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	1994.9-1997.6 PhD: China Pharmaceutical University 1997.7-1999.7 Postdoctoral: Peking University Published over 160 research papers Received 1 new drug certificate and 4 clinical research approvals Granted 8 patents Contributed to over 10 national textbooks First Prize in Natural Science by Ministry of Education (2009) Second Prize in Natural Science by Ministry of Education (2012) Supervised 6 award-winning PhD theses Listed in Elsevier's Most Cited Chinese Researchers (2014-2016)
Work Experience	1992.7-1994.8 - China Pharmaceutical University - Lecturer 1997.7-1999.7 - Peking University - Postdoctoral Researcher 1999.8-2006.7 - Peking University - Associate Professor 2001.9-2003.10 - National University of Singapore/Johns Hopkins International Medical Center - Research Scientist 2004.12-2005.3 - Toyama Medical and Pharmaceutical University, Japan - Visiting Scholar 2006.8-present - Peking University - Professor and Doctoral Supervisor 2010.7-present - Peking University - Deputy Secretary of the Party Committee of the School of Pharmaceutical Sciences 2011.12-present - Peking University Health Science Center - Deputy Chairman of the Trade Union 2012.2-present - Peking University - Member of the Trade Union Standing Committee
Awards	First Prize in Natural Science by Ministry of Education (2009) Second Prize in Natural Science by Ministry of Education (2012)

University/Lab Affiliation and Title

Peking University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

1994.9-1997.6 PhD: China Pharmaceutical University
1997.7-1999.7 Postdoctoral: Peking University
Published over 160 research papers
Received 1 new drug certificate and 4 clinical research approvals
Granted 8 patents
Contributed to over 10 national textbooks
First Prize in Natural Science by Ministry of Education (2009)
Second Prize in Natural Science by Ministry of Education (2012)
Supervised 6 award-winning PhD theses
Listed in Elsevier's Most Cited Chinese Researchers (2014-2016)

Work Experience

1992.7-1994.8 - China Pharmaceutical University - Lecturer
1997.7-1999.7 - Peking University - Postdoctoral Researcher
1999.8-2006.7 - Peking University - Associate Professor
2001.9-2003.10 - National University of Singapore/Johns Hopkins International Medical Center - Research Scientist
2004.12-2005.3 - Toyama Medical and Pharmaceutical University, Japan - Visiting Scholar
2006.8-present - Peking University - Professor and Doctoral Supervisor
2010.7-present - Peking University - Deputy Secretary of the Party Committee of the School of Pharmaceutical Sciences
2011.12-present - Peking University Health Science Center - Deputy Chairman of the Trade Union
2012.2-present - Peking University - Member of the Trade Union Standing Committee

Awards

First Prize in Natural Science by Ministry of Education (2009)
Second Prize in Natural Science by Ministry of Education (2012)

Areas of Focus	Tumor Stem Cells Tumor Drug Resistance Biopharmaceutics
Publications	Dual-functional drug liposomes in treatment of resistant cancers, Mu LM, Ju RJ, Liu R, Bu YZ, Zhang JY, Li XQ, Zeng F, Lu WL, 2017 The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer, Liu L, Mu LM, Yan Y, Wu JS, Hu YJ, Bu YZ, Zhang JY, Liu R, Li XQ, Lu WL, 2017 Lipid vesicles containing transferrin receptor binding peptide TfR-T12 and octa-arginine conjugate stearyl-R8 efficiently treat brain glioma along with glioma stem cells, Mu LM, Bu YZ, Liu L, Xie HJ, Ju RJ, Wu JS, Zeng F, Zhao Y, Zhang JY, Lu WL, 2017 Construction of functional targeting daunorubicin liposomes used for eliminating brain glioma and glioma stem cells, Zhao WY, Zhang CX, Liu L, Mu LM, Zeng F, Ju RJ, Xie HJ, Yan Y, Zhao Y, Lu WL, 2016 Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer, Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL, 2014 Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes, Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL, 2013 Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways, Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL, 2013 Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells, Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL, 2012 All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells, Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL, 2011 Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals, Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q, 2010

Areas of Focus

Tumor Stem Cells
Tumor Drug Resistance
Biopharmaceutics

Publications

Dual-functional drug liposomes in treatment of resistant cancers, Mu LM, Ju RJ, Liu R, Bu YZ, Zhang JY, Li XQ, Zeng F, Lu WL, 2017
The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer, Liu L, Mu LM, Yan Y, Wu JS, Hu YJ, Bu YZ, Zhang JY, Liu R, Li XQ, Lu WL, 2017
Lipid vesicles containing transferrin receptor binding peptide TfR-T12 and octa-arginine conjugate stearyl-R8 efficiently treat brain glioma along with glioma stem cells, Mu LM, Bu YZ, Liu L, Xie HJ, Ju RJ, Wu JS, Zeng F, Zhao Y, Zhang JY, Lu WL, 2017
Construction of functional targeting daunorubicin liposomes used for eliminating brain glioma and glioma stem cells, Zhao WY, Zhang CX, Liu L, Mu LM, Zeng F, Ju RJ, Xie HJ, Yan Y, Zhao Y, Lu WL, 2016
Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer, Ju RJ, Li XT, Shi JF, Li XY, Sun MG, Zeng F, Zhou J, Liu L, Zhang CX, Zhao WY, Lu WL, 2014
Modulation of drug-resistant membrane and apoptosis proteins of breast cancer stem cells by targeting berberine liposomes, Ma X, Zhou J, Zhang CX, Li XY, Li N, Ju RJ, Shi JF, Sun MG, Zhao WY, Mu LM, Yan Y, Lu WL, 2013
Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways, Li N, Zhang CX, Wang XX, Zhang L, Ma X, Zhou J, Ju RJ, Li XY, Zhao WY, Lu WL, 2013
Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells, Zhang L, Yao HJ, Yu Y, Zhang Y, Li RJ, Ju RJ, Wang XX, Sun MG, Shi JF, Lu WL, 2012
All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells, Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL, 2011
Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals, Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q, 2010

Tumor Stem Cells Cancer Drug Resistance Biopharmaceutics Liposome Drug Delivery Molecular Pharmaceutics Tumor Regulation Nanomedicine Pharmaceutical Sciences Targeted Therapy

Wei Wu - Fudan University

Fuqiang Hu - Zhejiang University

Hua Zhang - Peking University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us